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1. Introduction 
1.1 Epidemiology and cost of metastatic disease 
The American Cancer Society estimates that approximately 1.5 million people in the United 
States will be diagnosed with cancer, and 560,000 will die of cancer in 2010 (Jemal et al., 2010). 
These numbers are projected to increase rapidly in the near future due to national 
demographics with a large number of Americans reaching retirement age over the next 15-20 
years, resulting in a doubling of projected new cancer diagnoses in 2050 to 3 million (Hayat et 
al., 2007). Most cancer deaths involve extensive locoregional tumors or metastatic disease to 
brain, lung, liver, or bone causing pain, disability, and decreased quality of life. As treatments 
for cancer improve, patients are living longer with advanced cancer than ever before, and the 
management of metastatic disease is becoming increasingly more multi-disciplinary and 
complex with patients treated simultaneously with systemic therapy, surgery, and radiation. It 
is well documented that cancer-related pain is often inadequately controlled in the palliative 
care setting, and both the pain and opioid medication interfere with patient function and 
quality of life (Bruera & Kim, 2003; Cleeland et al., 1994; McGuire, 2004). Radiotherapy is an 
important treatment for the alleviation of pain and suffering for cancer patients. It prevents 
pathologic bone fractures, and palliates tumor-induced obstruction, bleeding, and pain that is 
not well palliated with pharmacologic treatment (Halperin et al., 2008). 
The skeleton is one of the most common sites of metastatic disease and is often the first site 
affected by metastases and the most common origin of cancer-related pain (Schulman & 
Kohles, 2007; Coleman, 2006). It was estimated that in 2004, 250,000 cancer patients were 
afflicted with metastatic bone disease (Schulman & Kohles, 2007). Bone metastases are most 
common in patients with multiple myeloma, of whom 90% develop bone metastases 
(Lipton, 2010). Approximately 70% of patients dying of breast and prostate cancer have 
evidence of metastatic bone disease, and bone metastases are also common in thyroid, 
kidney, and lung cancers, occurring in 30-40% of these cancers (Coleman, 2006). Metastatic 
bone disease causes considerable morbidity in patients with cancer, resulting in pain, 
hypercalcemia, pathologic fractures, compression of the spinal cord or cauda equina, and 
spinal instability (Coleman, 2006).  
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The treatment of metastatic bone disease is financially costly. Schulman and Kohles 
estimated that the mean per patient direct cost for cancer patients after diagnoses with 
metastatic bone disease was $75,329 compared to $31,455 for cancer-matched controls 
without metastatic bone disease (Schulman & Kohles, 2007). Using this data, the authors 
estimated that the national cost burden for patients with metastatic bone disease was $12.6 
billion in 2004, which was 17% of the NIH-reported $74 billion direct medical costs for 
cancer (Schulman & Kohles, 2007). These costs will clearly increase with our aging 
population and associated increase in cancer prevalence (Hayat et al., 2007). From a societal 
standpoint, looming Medicare financial constraints will likely result in reduced 
reimbursement for palliative services, driving the economic incentive to develop the next 
generation of more clinically efficient palliative radiotherapy workflows.  
2. Standard palliative radiotherapy techniques 
2.1 Lack of dose conformality 
For 30-40 years, standard palliative radiotherapy treatment techniques have utilized simple 
opposed beam arrangements such as treating a patient with parallel opposed anterior and 
posterior beams. Although simple to plan and deliver, such techniques provide poor 
conformality, and large volumes of organs at risk (OARs) may receive the full prescribed 
dose depending on the area treated. See Figure 1. Radiation to these OARs (skin, lung, 
esophagus, trachea, stomach, small bowel, rectum, bladder, or genitals) may result in cough, 
dysphagia, odynophagia, nausea, vomiting, weight loss, fatigue, diarrhea, dysuria, 
erythema, and pruritus of the skin and genitals (Gaze et al., 1997; Langendijk et al., 2000). 
Despite being planned and delivered on sophisticated systems, these treatments are 
frequently only moderately effective, and cause significant toxicity to an already ill patient 
population with a limited life expectancy (Gaze et al., 1997).  
2.2 Slow treatment planning and quality assurance workflow 
Conventional simulation and treatment planning is performed over a several day process 
prior to the first delivered treatment. The patient is first seen in consultation and scheduled 
for a CT simulation on a subsequent day. During the CT simulation the patient is placed in 
the position in which they will ultimately be treated on a treatment unit, and immobilization 
and support devices are fabricated, after which they undergo a CT scan in the treatment 
position. He or she must then wait, sometimes several days, for the contouring of the CT 
simulation images, a process by which the radiation oncologist specifies the planning target 
volume (PTV) of the tumor to be treated and the regional OARs or adjacent tissues that may 
receive radiation resulting in toxicity. Following the contouring of the CT images, radiation 
treatment planning is performed, during which time medical dosimetrists and physicians 
determine the beam angles and treatment techniques to deliver the prescribed dose to the 
PTV while attempting to minimize dose to OARs if possible. Following treatment planning, 
quality assurance calculations and/or measurements are performed by medical physicists 
before delivery of the first treatment to ensure accuracy of delivering the planned dose and 
ensure patient safety. Finally, the first treatment is then delivered 3-7 working days after the 
initial consultation. 
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2.3 Inconvenient, modestly effective treatments 
Although fractionation schedules in Europe are trending toward hypofractionation (fewer 
treatments), the most common palliative dose fractionation schedules in the United States vary 
between 20 and 30 gray (Gy) in 5 -10 fractions delivered over 1 -2 weeks (Fairchild et al., 2009). 
Adding the one week pre-treatment work process to the 1-2 weeks of treatment delivery 
results in an overall duration of 2-3 weeks for completion of palliative treatment. Conventional 
radiotherapy, regardless of fractionation schedule, has been found to be modestly effective in 
treatment of bone metastases, resulting in an improvement in pain in only about 60% of 
patients (Wu et al., 2003; Chow et al., 2007). In a retrospective study of end stage cancer 
patients receiving palliative radiotherapy, Gripp et al found that half of the patients received 
treatment for >60% of their final days of life (Gripp et al., 2010). Thus, these often modestly 
effective treatments subject the patients to repeated visits to the treatment center and consume 
precious time and energy for ill patients and their families. Clearly it is important that we 
design more effective palliative treatments that are more efficient to plan and deliver, 
minimize acute toxicity, and require fewer total treatments and time.  
2.4 Mark-and-start radiation therapy workflows 
Traditional emergent radiation therapy workflows referred to as “mark and start” protocols 
were developed to rapidly treat patients with severe pain, spinal cord compression, superior 
vena cava syndrome, and life-threatening obstruction of major organs. They generally rely 
on a good understanding of surface anatomy to direct placement of square or rectangular 
treatment fields on the patient with the patient on the treatment couch. A port film is 
obtained to confirm that the target is being treated and to document the treatment volume. 
The treatment field is then marked on the patient and documentation photos are obtained. 
Following anatomic volume determination and verification, the prescription dose is 
converted to treatment unit monitor units which are calculated using the field size, 
treatment distance, treatment depth, and machine-specific output factors for a given photon 
energy. The best quality assurance practices are to have two people calculate the monitor 
units independently and to have at least one person perform the calculation by hand if a 
computer calculation program is used. Once the monitor units are calculated, the patient can 
be treated. Emergent treatments generally use one or two parallel opposed beams to deliver 
non-conformal dose with large volumes of non-target tissue being irradiated to the 
prescribed dose.  
Since most patients treated with radiation therapy on an emergent basis are symptomatic 
with pain, bleeding, or obstruction, it can be difficult for them to lie still on a flat treatment 
table for prolonged periods of time. Therefore, the faster the clinical workflow, the better the 
patient will tolerate the process. Most new linear accelerators (LINACs) are equipped with 
kilovoltage imaging capabilities on the treatment unit which can make the initial field 
placement easier by functioning similar to a CT or fluoroscopic simulator. This can increase 
the efficiency of the process since accurate field placement is the most time consuming part 
of the “mark and start” workflow. Once the field is accurately marked, the monitor unit 
calculations take only a few minutes, and the patient can rapidly be treated.  
Clearly, for emergency situations, a simple treatment option is highly desirable for any 
treatment system, especially for a system in a one-unit radiation oncology clinic. Some 
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complex treatment systems have no easy methodology or workflow to treat patients 
emergently with simple fields if the patient has not undergone a separate CT simulation. 
This is due to the fact that they have no way to calculate a treatment plan without a 
contoured CT image dataset. In addition, some intensity modulated radiation therapy 
(IMRT) dedicated systems with their own CT treatment planning algorithms do not have an 
easy way to perform an independent calculation to verify the accuracy of the planned dose 
calculation. Due to these limitations, the treatment of the emergency patient on these 
systems generally requires performance of the standard workflow of CT simulation, CT 
contouring, dose calculation, dose verification with unit measurements, and then image 
guided treatment delivery to the patient. The development of novel and greatly expedited 
workflows for these systems that utilize conformal dose delivery would provide an 
improved method to treat emergency patients that could also be used to treat non-emergent 
palliative patients more rapidly. In this chapter, we propose the development of one 
potential rapid clinic workflow utilizing the TomoTherapy system called STAT RAD.  
3. Stereotactic Body Radiotherapy (SBRT): A more effective, highly 
conformal hypofractionated palliative radiation technique 
In the search for more effective and less toxic radiotherapy techniques, much attention has 
been focused on stereotactic body radiotherapy (SBRT). SBRT utilizes hypofractionated, highly 
conformal, high dose radiation delivery that has been modeled after intracranial stereotactic 
radiosurgery (SRS). Like SRS, SBRT uses multiple beams that converge on the target volume. 
This minimizes the volume of tissue receiving high dose to where the beams intersect, 
reducing dose to normal tissue. This allows for the delivery of ablative doses of radiation in a 
few fractions with acceptable toxicity (Read, 2007; Timmerman et al., 2010). SBRT is a proven 
method for treating lung cancer, yielding excellent rates of local control for non-small-cell lung 
cancer and resulting in 5-year survival rates potentially comparable to that of surgery 
(Timmerman et al., 2010; Onishi et al., 2010). In addition, the treatment of liver metastases with 
SBRT has yielded promising results, achieving local control rates at 2 years of approximately 
70–90% (Dawood, Mahadevan, & Goodman 2009; Rusthoven et al., 2009).  
SBRT has also been used in the palliative treatment of bone metastases to the spine with 
remarkable success. Multiple studies have used SBRT to safely deliver high doses of 
radiation to spinal metastases while significantly limiting dose to the spinal cord and 
achieving local control rates of >80% at one year (Gerszten et al., 2007; Nelson et al., 2009; 
Gibbs et al., 2007). Fractionations in these studies have ranged from 1 to 5 fractions 
delivering 4 – 24 Gy per individual fraction, with total doses between 10 to 30 Gy (Gerszten 
et al., 2007; Nelson et al., 2009; Gibbs et al., 2007). In the largest prospective study of spine 
SBRT by Gerszten, 336 cases were treated primarily to relieve pain, and they achieved 
significant pain improvement in 290 patients (86%). Nelson, Gibbs, and Ryu, have also 
reported pain reduction in greater than 80% of patients in their studies (Gerszten et al. 2007; 
Nelson et al., 2009; Gibbs et al., 2007; Ryu et al., 2008), much improved over the 60% in 
conventional radiotherapy (Wu et al., 2003; Chow et al., 2007). Not only do more people 
experience pain relief with SBRT, but the pain relief is reported to be more durable. Gagnon 
demonstrated statistically significant improvement in pain scores lasting throughout 4 years 
of follow-up (Gagnon et al., 2009). Ryu found the median duration of pain relief to be 13.6 
months with SBRT (Ryu et al., 2008), which is a dramatic improvement compared to the 
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average 3 to 6 months of palliation with conventional therapy (Gaze et al., 1997; Foro 
Arnalot et al., 2008). Additionally, spinal SBRT treatments have been effective in achieving 
local control in tumors typically resistant to radiotherapy, such as renal cell carcinoma and 
melanoma, reportedly due in part to radiation injury to the tumor vasculature (Gerszten et 
al., 2007; Gibbs et al., 2007; Ryu et al., 2008; Gagnon et al., 2009).  
3.1 Adverse events with SBRT: Minimal toxicity 
Though great success is seen in high dose, hypofractionated therapy, care must be taken to 
avoid incorrectly delivering the high dose radiation to normal tissue. Prevention of damage 
to normal tissue is ensured through careful patient immobilization, co-registration of 
multiple diagnostic imaging modalities (MRI, PET CT, contrast enhanced CT) to the kVCT 
simulation to accurately define the target and OARs, inverse treatment planning with the 
use of intensity modulated radiation therapy, patient-specific quality assurance, and CT 
image guidance at the time of treatment delivery. Nevertheless, common side effects of 
radiotherapy can occur with SBRT. However, the advantage of conformal radiation is that it 
spares high radiation dose to normal tissue with the relatively small target volumes 
employed in this technique compared to parallel opposed techniques in which prescription 
doses are delivered to all tissues, target and OARs, in the beam path through the patient. 
This advantage of SBRT has been demonstrated in many trials by reports of little to no 
toxicity (Gerszten et al., 2007; Gagnon et al., 2009), and is reinforced by the findings of 
McIntosh et al, who compared conformal TomoTherapy to conventional 3D conformal 
treatment techniques on an anthropomorphic phantom and showed that TomoTherapy 
plans significantly improved conformality and reduced dose to regional critical structures 
(McIntosh et al., 2010). 
Most significant adverse events in spinal SBRT have occurred with treatments that used 
extremely high-doses (>20 Gy) in a single fraction. Gomez et al reported odynophagia and 
dysphagia in 1 patient who had received 22 Gy to the esophagus in a single dose, and 
another patient developed an esophageal ulcer and necrosis after receiving 24 Gy to his 
esophagus in one fraction (Gomez et al., 2009). Another patient developed bronchial stenosis 
after receiving 11 Gy to a bronchus in a single fraction. In another study with similarly high 
dose fractionation schedules, 39% of patients treated with 18 to 24 Gy in a single dose 
developed new or progressive vertebral fractures (Rose et al., 2009). However, their patient 
selection did not utilize a scoring system to identify patients at high risk for pathologic 
fracture, such as the Mirels scoring system (Cumming et al., 2009). In contrast, Gagnon et al, 
using mean doses of 26 Gy in 3 fractions in 200 patients, only had 2 patients (1%) develop 
vertebral fractures (Gagnon et al., 2009). Sahgal et al reported 5 cases of radiation 
myelopathy and concluded that for single fraction SBRT, up to 10 Gy to a maximum point to 
the thecal sac is safe (Sahgal et al., 2010).  
3.2 Extrapolation of spinal SBRT-like dose distributions to non-spine metastases 
Given the advances in radiation delivery with SBRT and its success in palliation of spine 
metastases, it is logical to apply these advancements in technology to extra-axial bone 
metastases; however, no trials have been published to date. This is due to the fact that SBRT 
is only reimbursed for limited indications such as spinal metastases. It is fair to hypothesize 
that the extrapolation of SBRT-like dose distributions to extra-axial bone metastases will 
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improve pain control and that rapid institution of radiation will minimize the time patients 
are in pain and on high dose opioids that place them at risk for iatrogenic medical 
complications. By applying the concepts of spinal SBRT, highly conformal hypofractionated 
radiation therapy plans could be used to treat non-spinal metastases. This allows for 
increased dose per fraction and fewer total fractions with less toxicity compared to standard 
non-conformal palliative regimens. See Figures 1-2.  
 
Fig. 1. Nonconformal Technique 
 
Fig. 2. Conformal Technique 
3.3 Relative Biologic Effective Dose: A method to compare different dose 
fractionation schedules 
Based on the linear-quadratic equation, one can calculate the biologic effective dose (BED) to 
compare dose delivery of different fractionation schedules using the equation: 
 BED = nd [1+d(alpha/beta)]  (1) 
n = number of fractions, d = dose per fraction, alpha/beta = the ratio of intrinsic 
radiosensitivity to repair capacity 
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As seen in Table 1, when compared with conventional fractionation schedules for palliative 
osseous metastases, such as 30 Gy in 10 fractions or 20 Gy in 5 fractions, high dose per 
fraction regimens deliver very similar BED to early responding tissues and slightly higher 
BED to late responding tissues. We believe that for reasonable rates of symptom relief and 
duration of palliation that palliative regimens should deliver a minimum BED of 25 Gy to 
most treatment targets. Twenty-four Gy in 3 fractions (8 Gy x 3 fractions) is an attractive 
palliative regimen that balances a high radiobiologic dose with the convenience of a highly 
hypofractioned regimen. This daily dose can generally be delivered in 10 minutes or less 
depending on target size and modulation allowing patients in pain to tolerate the treatment 
without moving. Finally, doses of 8 Gy or higher may be more effective against tumor 
histologies thought to be more radioresistant such as melanoma or renal cell carcinoma due 
to cytotoxic effects to the tumor vasculature. However, the dose per treatment, number of 
treatments, and total dose will depend on the patient’s overall condition and tumor-specific 
factors including histology, location, proximity to critical OARs, and size. Relative BED 
provides a method to compare different dose fractionation schedules that can be used to 
correlate the treatment with patient outcomes. 
 
 Total dose # of fractions 
Dose per fraction 
(Gy) 
Alpha/beta BED 
Early 
Responding 
Tissues 
30 10 3 10 39 
20 5 4 10 28 
24 3 8 10 43 
Late 
Responding 
Tissues 
30 10 3 3 60 
20 5 4 3 47 
24 3 8 3 88 
Table 1. Comparison of BED in Different Palliative Fractionation Schedules 
4. STAT RAD: A rapid palliative radiotherapy workflow in clinic development 
Clearly a faster, more efficient workflow to treat metastatic disease is needed. Patients with 
widespread metastases frequently have short life expectancies and need treatments that 
minimize their time in clinic while providing rapid and durable pain relief for the remainder 
of their lives. Additionally, this need for efficiency will further rise with the increasing 
cancer burden and health care costs due to the aging baby-boom population. 
Thus, at the University of Virginia we are piloting a new workflow called “STAT RAD” to 
rapidly deliver advanced radiotherapy to patients with metastatic disease on an internal 
review board approved clinical trial. This STAT RAD workflow offers same-day palliation 
in an approximately 6-hour time frame similar to a standard GammaKnife ® (Elekta, 
Stockholm, Sweden) workflow. STAT RAD is a highly coordinated conventional workflow 
that includes kVCT simulation, treatment planning, treatment plan quality assurance, and 
delivery of conformal hypofractionated radiotherapy in a single day. All treatments are 
planned and delivered on FDA-approved systems including the TomoTherapy treatment 
machine. This workflow allows patients to receive an entire course of palliative treatment 
from start to finish in a few days, a process that conventionally takes 2-3 weeks. Since 
patients are billed for each individual treatment, requiring fewer treatments reduces health 
care costs in addition to being more convenient. With the STAT RAD program we are now 
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able to offer a unique workflow that delivers rapid, effective, and efficient palliative 
radiotherapy that is cost effective, less toxic, and more convenient for cancer patients and 
their families.  
We have treated approximately 50 cancer patients with the conformal hypofractionated 
STAT RAD treatment regimen for a variety of palliative indications. We have treated 
patients with IMRT and 3D delivery using TomoHelical and TomoDirect planning modes. 
Retrospective review of these patients shows that the majority of these patients experienced 
rapid and durable palliation of symptoms with minimal toxicity (unpublished data). In 
general, patients are extremely satisfied with the speed at which their treatment is initiated 
and the convenience of the hypofractionated regimens.  
In our current trial we are quantifying patient outcomes following treatment with the 
current STAT RAD workflow in an effort to determine its benefits and risks to patients. In 
addition, we are systematically evaluating and optimizing software and hardware necessary 
to make the STAT RAD workflow even more efficient. 
4.1 Technologic rationale for the choice of the TomoTherapy platform   
The TomoTherapy platform has been chosen for the STAT RAD workflow for a variety of 
reasons. TomoTherapy delivers highly conformal and homogenous dose distributions 
through modulation of dose from a bank of 64 binary 6.25-mm-wide collimator leaves 
capable of pneumatic opening or closing 51 times per revolution as the gantry revolves 
around the patient. The system can also treat patients with discreet beam angles (i.e. the 
radiation beam not rotating) in a mode called TomoDirect. Although all TomoTherapy 
treatment delivery is technically IMRT, the treatment planning can be done in either a 3D or 
IMRT mode allowing highly conformal treatments to be billed as 3D and thus used in the 
treatment of all patients with bone metastases. While the 3D planning mode limits the 
planning options for dose constraints on OARs, partial and complete blocking can be 
assigned to non-target structures. Partial blocking allows beams to exit through the structure 
after treating the PTV but not to enter through the structure prior to treating the PTV, and 
complete blocking restricts beams from entering or exiting through a structure. In addition, 
good preliminary data exists to support the use of the fan beam MVCT as a CT simulation 
image set for treatment planning and the use of CT detector-based exit dose methodology 
for quality assurance, making this system an excellent platform to pilot and optimize this 
workflow. 
5. Scan-plan-verify-treat STAT RAD workflow: A novel and more efficient 
STAT RAD workflow 
With recent advances in software and technology, we plan to further condense the STAT 
RAD workflow into the Scan-Plan-Verify-Treat workflow, a 30-minute process in which all 
steps (MVCT simulation, diagnostic image co-registration, treatment planning, and 
treatment delivery with real time quality assurance) are performed on the TomoTherapy 
unit. This advanced workflow will eliminate the need for the patients to undergo a kVCT 
simulation on a separate unit as well as make it unnecessary for the patient to leave the 
treatment table between the simulation and treatment.  
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Requirements for the clinical implementation of the Scan-Plan-Verify-Treat STAT RAD 
workflow are envisioned as follows: 
1. Scan: MVCT simulation image acquisition (10 minutes) then rigid or deformable image 
co-registration of existing diagnostic image sets with pre-contoured target and OAR 
volumes to the MVCT simulation scan for contour transfer (3-5 minutes).  
2. Plan: Rapid inverse treatment planning (3-5 minutes). 
3. Verify: Real-time patient-specific quality assurance using CT detectors prior to or 
during treatment delivery (10 minutes). 
4. Treat: Simple real-time patient motion tracking to monitor patient position real-time 
during the Scan-Plan-Verify-Treat process to ensure accurate delivery.  
5.1 New image co-registration workflow 
In the conventional workflow, target volumes and OARs are contoured on recent diagnostic 
images (MRI, PET-CT, or diagnostic CT that are already available in the patient’s electronic 
radiology chart). After the patient undergoes a kVCT simulation, the contoured diagnostic 
images are rigidly or deformably co-registered to the kVCT simulation images, and the 
contours are transferred. This allows for high resolution diagnostic images to be used for 
tumor and normal tissue identification, which are not always possible to differentiate on CT 
simulation scans due to the resolution of standard wide bore CT simulation scanners and 
images that are frequently obtained without intravenous contrast. Multiple commercial 
image processing systems are available for this image processing, and we are currently 
using Velocity® (Atlanta, GA) image processing software. Following treatment planning, 
the patient then undergoes image guided treatment delivery, a process in which a daily 
MVCT scan is obtained on the TomoTherapy unit and co-registered to the planning kVCT 
scan. Patient setup shifts can then be made to ensure accurate patient setup, and the patient 
is treated. Therefore, this is a two image co-registration workflow. See Figure 3. 
 
Fig. 3. Comparison of Image Co-Registration Workflows 
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A kVCT simulation scan has historically been used for simulation in the conventional 
workflow for both palliative and curative radiation planning. Compared to MVCT scans, it 
has higher resolution and allows the possibility for administration of iodinated IV and/or 
GI contrast, which makes it easier to identify soft tissues and bony anatomy for treatment 
planning. However, contrast agents are not generally given for kVCT simulations of patients 
for palliative treatment of metastases since the soft tissue and bone windows are adequate. 
Soft tissue and bone windows of MVCT scans have quite reasonable resolution and can 
easily be co-registered to higher resolution diagnostic studies for contour transfer. Software 
has been used clinically since 2004 to automatically co-register kVCT simulation images and 
daily MVCT scans for image guidance on a daily basis.  
Our preliminary unpublished data confirms that the MVCT scan has sufficient resolution, 
particularly of bone anatomy, for accurate co-registration to contoured diagnostic images 
and that this one step co-registration process yields comparable agreement to the 
conventional two step image co-registration workflow with +/- 2-3 mm differences. See 
Figure 3. This level of agreement is consistent with results reported from image co-
registration studies performed on a multi-institutional pediatric clinical trial with co-
registration data of 51 patients from 45 institutions using 11 different image software 
systems. They reported an inherent uncertainty of 2 mm for MRI to CT co-registration (Ulin, 
Urie, & Cherlow 2010). Thus, preliminary data suggests that the optimization of this one 
step image co-registration workflow of diagnostic image sets to a MVCT simulation scan 
will be clinically similar to the conventional two image co-registration workflow. MVCT 
image guidance scans and kVCT simulation co-registration occurs routinely in the clinic and 
only takes a few seconds, therefore, we do not believe that this will be a rate-limiting step in 
the clinical implementation of the Scan-Plan-Verify-Treat STAT RAD workflow. Further 
optimization of the image co-registration workflow will make the 30-minute Scan-Plan-
Verify-Treat STAT RAD workflow feasible.  
5.2 Rapid inverse treatment planning on MVCT scans 
CT image sets are used for radiation treatment planning because the electron density of 
tissues, which is required for calculating dose, is easily determined based on the Hounsfield 
units. The tissue electron density determination is essentially the same for MVCT and kVCT 
scans. It has previously been reported that as far as the dose calculations are concerned, 
treatment planning on either a kVCT simulation image set or a MVCT simulation image set 
yields treatment plans that are within 1% of each other (Langen et al., 2005).  
We have recently published that the TomoTherapy STAT RT treatment planning module 
can calculate SBRT plans in just a few minutes (Dunlap et al., 2010). The computing speed of 
radiation treatment planning systems is about to take a quantum leap forward with the 
incorporation of new algorithms that will take advantage of the processing power of 
graphics processing units (GPU) whose more rapid and parallel calculating potential can 
improve treatment planning speed by 10-20 times (Hissoiny, Ozell, & Despres, 2010; 
Hissoiny, Ozell, and Despres, 2009). Same-day inverse treatment planning of IMRT or 3D 
TomoTherapy plans has not been a problem for patients treated with STAT RAD to date. 
We are comparing planning times for current FDA-approved treatment planning systems to 
those of newer, in-development GPU-based algorithms. In general, highly conformal 3D or 
IMRT plans can be generated in 2-3 minutes with GPU-based algorithms.  
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We have shown that accelerated treatment planning software for Helical TomoTherapy 
provides clinically acceptable dosimetry, with conformality and homogeneity that is 
superior to standard LINAC-based 3D conformal planning and is only slightly inferior to 
standard Helical TomoTherapy dosimetry (McIntosh et al., 2010). We have also shown that, 
with planning times of 2-5 minutes, this accelerated treatment planning software provides 
levels of dosimetric conformality, heterogeneity, and avoidance of organs at risk for simple 
SBRT treatments that are clinically equivalent to those generated with conventional Helical 
TomoTherapy treatment planning (Dunlap et al., 2010). This preliminary data supports that 
treatment planning speed is not likely to be rate limiting in the ultimate clinical 
implementation of the Scan-Plan-Verify-Treat STAT RAD workflow.  
5.3 Novel CT-detector-based quality assurance methodology 
Current standard of care TomoTherapy quality assurance methodology requires that each 
patient-specific treatment plan be delivered to a cylindrical plastic phantom with ion 
chamber and film measurement to ensure geometric and planar dose distribution accuracy 
using gamma criteria of 3%/3mm. However, this method does not measure the dose that 
the patient is receiving during treatment or provide full 3D dose verification. It causes 
another delay in delivering the first treatment to the patient as it requires approximately 30 
minutes to complete, and is generally done by a medical physicist after daily clinic patient 
treatment is finished. A methodology to monitor the patient exit dose in real time would 
increase patient safety through verification of daily treatment accuracy as well as expedite 
the treatment workflow. Clearly, a real-time quality assurance methodology that does not 
require moving the patient off the TomoTherapy treatment couch for phantom 
measurements is essential for the development of a 30-minute Scan-Plan-Verify-Treat 
workflow. Current dose verification methodologies measuring dose at the time of patient 
treatment are limited to point measurements on the patient surface (Essers & Mijnheer, 
1999), which is rarely in the target volume or a critical OAR, or through expensive 
implanted dosimeters (Beyer et al., 2007; Scarantino et al., 2004), which are not practical for 
most palliative patients. Since there is no method to directly measure the three dimensional 
dose in the patient, alternative approaches are being developed and tested in academic 
clinical settings. These alternative approaches reconstruct the delivered three dimensional 
dose distribution based on the measurement of either entrance or exit dose and back-
projecting the measurements onto simulation or image guidance CT image sets.  
The opportunity to reconstruct dose from information collected during treatment became 
available with the incorporation of radiation imaging detectors, such as electronic portal 
imaging devices (EPID) on linear-accelerators and CT detector arrays on TomoTherapy. 
Dose reconstruction using in-line EPID was first described by McNutt et al (McNutt, 
Mackie, & Paliwal 1997; McNutt et al., 1996). The EPID, when deployed during treatment, 
collects exit fluence from the patient and then back-projects this to X-ray fluence before 
entering the patient; then, the dose in the patient is re-computed using this entrance fluence 
and the planning CT images. However, there are many limitations to EPID-based dose 
verification. For example, the EPID was originally designed for semi-quantitative portal 
imaging; and for the purpose of dose reconstruction, it suffers from a narrow dynamic 
range, short life span, non-linearity in the dose response, ghost artifacts from low temporal 
resolution, and cross-plane scatter photon contribution to the measured fluence (Mijnheer, 
2008). Investigators are currently working on methods to overcome these challenges.  
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The TomoTherapy unit has an in-line source-patient-detector geometry with CT ion 
chamber detectors that are used for daily MVCT scan image guidance for accurate patient 
positioning that remain in place during both imaging and treatment. These CT detectors can 
also be used to measure the patient exit dose fluence and back-project this onto a planning 
CT scan for volumetric or 3D dose reconstruction. Dose verification on TomoTherapy was 
first studied by Kapatoes et al., who calculated the entrance fluence from the exit dose using 
a transfer matrix, which is calculated based on the radiological path length from the source 
to the detector (Kapatoes et al., 2001; Kapatoes et al., 2001). The use of a CT ion chamber 
array has multiple advantages over EPID for exit fluence measurement. It is more durable, 
and has a much longer life span. It has a wider dynamic range and doesn’t limit treatment 
positions. Finally, it is less sensitive to the noise from cross-plane scatter photons that 
complicate EPID-based dose reconstruction (Siewerdsen & Jaffray 2001).  
Our pre-clinical evaluation of the CT detector-based exit radiation dose verification 
algorithm has been retrospectively studied by Sheng et al. using in-development software 
(Sheng et al., 2011). We compared planned and delivered doses with the conventional 
phantom quality assurance measurements for 24 patients and 347 treatment fractions. The 
concordance of planned to delivered dose calculated by the in-development software was 
shown to be +/- 5% (Sheng et al., 2011). This tolerance is within the standard of care of other 
current clinically available quality assurance methods. Further refinements are expected to 
improve dose monitoring accuracy for this or other algorithms. 
5.4 Optical tracking methods for patient intra-fractional motion monitoring 
Consistent patient positioning during CT image acquisition and treatment is critical to 
ensure accurate dose delivery. Physical immobilization devices such as external body 
frames, aquaplast masks and other body molds, and vac-lock vacuum bags are commonly 
used to ensure patient positioning reproducibility. X-ray or CT image guidance prior to 
radiation delivery on the treatment unit is routinely employed in the clinic. Methods for 
optical tracking of markers on the patient surface or tracking of the patient’s skin surface 
itself are available to ensure consistent patient positioning after image guidance and during 
treatment, known as intra-fractional motion (Wagner et al., 2007; Wiersma et al., 2010). This 
provides a method without ionizing radiation for confirming patient position that can be 
used real-time during treatment delivery. With this information, if the patient’s position 
moves outside of acceptable limits in any direction, treatment could be paused. A 
mechanism to ensure that the patient’s position doesn’t change between MVCT simulation 
and treatment delivery would obviate the need for a repeat image guidance MVCT scan just 
prior to delivery in the Scan-Plan-Verify-Treat workflow.  
We have recently developed an in-house optical tracking system using multiple OptiTrack 
FLEX:V100 cameras (Natural Point, Corvallis, OR). The camera utilizes 26 infrared light-
emitting diodes and a charge coupled device to capture the reflective light from markers 
with special coating. By using multiple cameras, the 3D position of each reflective marker 
can be determined precisely. Multiple markers can be placed on a patient and monitored 
simultaneously. In the lab, localization precision of 0.1 mm was achieved (unpublished 
data). Through strategic positioning of the markers, movements of the head, neck, and 
extracranial locations can be closely monitored.  
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6. Clinical benefits and future directions of STAT RAD implementation 
6.1 Additional benefits to patients with metastatic disease 
Several advantages of this streamlined workflow are envisioned that will improve the 
care of patients with metastatic disease. The most obvious is that patients who live far 
from treatment centers can be offered palliative radiation therapy as an option. Take for 
example the case of a patient who lives 50 miles from a radiation oncology center. If they 
are seen in consultation, undergo a CT simulation on a second visit, and then are treated 
with 30 Gy in 10 fractions, they will have to drive 1200 miles for this treatment course. 
Clearly this is not practical for many ill patients in the last few months of life. If they can 
receive a conformal high dose palliative treatment in one day, it is much more likely that 
they will receive this treatment. We have been coordinating STAT RAD treatments on 
days that patients have appointments with other oncologists or specialists. Patients come 
to the radiation oncology clinic and undergo a consultation and CT simulation and then 
go to their other appointments while planning and quality assurance measurements are 
performed, and then they return to the radiation oncology clinic later that same day for 
treatment. Once the Scan-Plan-Verify-Treat STAT RAD workflow is available, we envision 
treating patients at the end of the scheduled workday on a same-day physician request 
basis. This service holds high utilization potential because many times physicians do not 
know if a patient is in significant need of palliation until they examine the patient at the 
time of a scheduled appointment.  
Frequently patients are admitted to the hospital for management of cancer-related 
symptoms such as intractable pain, spinal cord compression, profuse tumor bleeding, or 
tumor related acute obstruction. These patients are frequently treated with palliative 
radiation therapy. The STAT RAD workflow enables patients to receive high dose and 
conformal treatments that start faster than conventional kVCT simulation workflows and 
can shorten the length of hospitalization to complete treatment.  
Finally, this workflow makes the treatment of patients with oligometastatic disease more 
streamlined and practical because it enables SBRT-like dose distributions to be delivered to 
multiple lesions that currently cannot be treated with SBRT, such as nodal disease or non-
spinal bone metastases.  
6.2 Incorporation of translational technology development into routine clinic care for 
all patients 
Several aspects of the Scan-Plan-Verify-Treat STAT RAD clinical development can be 
incorporated into the routine care of patients undergoing curative radiation therapy. 
Specifically, CT detector-based quality assurance of all treatments could be automated and 
performed daily. Such quality assurance could provide a warning if the delivered dose is 
greater than a threshold such as +/- 5% for a patient and trigger an investigation into the 
cause of this deviation. Quality assurance of each fraction of treatment would be a major 
advancement compared to current quality assurance methods of checking each plan prior to 
treatment. Using daily quality assurance to monitor changes in patient status such as 
significant weight loss in a head and neck cancer patient could trigger re-planning that 
could be done on an adaptive basis.  
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A simple system to monitor patient motion following image guidance could reduce the risk 
of geometric misses due to intra-fractional patient motion. If it were determined that a 
specific patient had more or less intra-fractional motion than accounted for in their PTV 
expansion, then their treatment plan could be adaptively re-planned to mirror their specific 
expansion requirements.  
6.3 Future directions for spinal SBRT 
The Scan-Plan-Verify-Treat STAT RAD workflow could easily be incorporated into the 
treatment of spinal SBRT patients. We have previously reported that treatment planning 
algorithms currently exist that can create highly conformal spinal SBRT plans in just a few 
minutes (Dunlap et al., 2010) and that the CT detector-based quality assurance algorithms 
can measure exit dose to within +/- 5% (Sheng et al., 2011). Real-time spinal SBRT 
simulation, planning, and delivery would eliminate the need for patients to be accurately re-
set up and positioned between simulation and treatment to within two millimeters of 
accuracy which is the current accuracy of most co-registration-based image guided systems. 
In addition, differences in pitch, yaw, or roll of the patient between simulation and 
treatment delivery setups cannot be routinely corrected by most CT-based image guidance 
systems, requiring the patient to be re-positioned and re-imaged prior to treatment if they 
are out of tolerance. With this proposed workflow, the patient could be treated in the 
planning position, which could potentially eliminate these re-positioning error issues.  
7. Conclusion 
As the cancer burden in the population increases and heath care costs continue to rise, a 
faster, more efficient workflow is needed to treat patients with metastatic disease. 
Conformal hypofractionated treatment has demonstrated promising results for the 
palliation of bone metastases, and its incorporation into a workflow such as the STAT RAD 
workflow also improves patient convenience. In the near future, we believe the optimization 
of new software and hardware will enable a 30-minute Scan-Plan-Verify-Treat STAT RAD 
workflow to further maximize patient convenience and efficiency. This more efficient and 
cost effective workflow may result in more widespread incorporation of palliative radiation 
for cancer patients failing systemic therapy earlier in their disease process, reducing pain 
and functional loss and improving quality of life.  
8. Abbreviations 
3D - 3-dimensional 
BED - biologic effective dose  
CT – computed tomography 
CTV – clinical target volume 
EPID - electronic portal imaging device 
FDA – Food and Drug Administration 
GI - gastrointestinal 
GPU - graphics processing unit 
Gy - gray  
IMRT- intensity modulated radiation therapy  
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IV - intravenous 
kVCT – kilovoltage CT 
LINAC - linear accelerator  
MRI – magnetic resonance imaging 
MVCT – megavoltage CT 
OAR - organ at risk 
PET CT – positron emission tomography CT 
PTV - planning target volume  
SBRT - stereotactic body radiotherapy  
SRS - stereotactic radiosurgery 
STAT RAD - urgent and rapid radiation treatment 
9. References 
Beyer, G. P., C. W. Scarantino, B. R. Prestidge, A. G. Sadeghi, M. S. Anscher, M. Miften, T. B. 
Carrea, M. Sims, & R. D. Black. (2007). Technical evaluation of radiation dose 
delivered in prostate cancer patients as measured by an implantable MOSFET 
dosimeter. International Journal of Radiation Oncology, Biology, Physics, Vol.69, No.3, 
pp. 925-35, ISSN 0360-3016 
Bruera, E. & H. N. Kim. (2003). Cancer pain. JAMA : The Journal of the American Medical 
Association, Vol.290, No.18, pp. 2476-9, ISSN 0098-7484 
Chow, E., K. Harris, G. Fan, M. Tsao, & W. M. Sze. (2007). Palliative radiotherapy trials for 
bone metastases: A systematic review. Journal of Clinical Oncology : Official Journal of 
the American Society of Clinical Oncology, Vol.25, No.11, pp. 1423-36, ISSN 1527-7755 
Cleeland, C. S., R. Gonin, A. K. Hatfield, J. H. Edmonson, R. H. Blum, J. A. Stewart, & K. J. 
Pandya. (1994). Pain and its treatment in outpatients with metastatic cancer. The 
New England Journal of Medicine, Vol.330, No.9, pp. 592-6, ISSN 1533-4406 
Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal 
morbidity. Clinical Cancer Research : An Official Journal of the American Association for 
Cancer Research, Vol.12, No.20, Pt.2, pp. 6243s-9s, ISSN 1557-3265 
Cumming, D., J. Cumming, A. Vince, & R. Benson. (2009). Metastatic bone disease: The 
requirement for improvement in a multidisciplinary approach. International 
Orthopaedics, Vol.33, No.2, pp. 493-6, ISSN 1432-5195 
Dawood, O., A. Mahadevan, & K. A. Goodman. (2009). Stereotactic body radiation therapy 
for liver metastases. European Journal of Cancer, Vol.45, No.17, pp. 2947-59, ISSN 
0959-8049 
Dunlap, N., A. McIntosh, K. Sheng, W. Yang, A. B. Turner, A. Shoushtari, J. Sheehan, et al. 
(2010). Helical tomotherapy-based STAT stereotactic body radiation therapy: 
Dosimetric evaluation for a real-time SBRT treatment planning and delivery 
program. Medical Dosimetry, Vol.35, No.4, pp. 312-9, ISSN 0958-3947 
Essers, M. & B. J. Mijnheer. (1999). In vivo dosimetry during external photon beam 
radiotherapy. International Journal of Radiation Oncology, Biology, Physics, Vol.43, 
No.2, pp. 245-59, ISSN 0360-3016 
Fairchild, A., E. Barnes, S. Ghosh, E. Ben-Josef, D. Roos, W. Hartsell, T. Holt, J. Wu, N. Janjan, 
& E. Chow. (2009). International patterns of practice in palliative radiotherapy for 
painful bone metastases: Evidence-based practice? International Journal of Radiation 
Oncology, Biology, Physics, Vol.75, No.5, pp. 1501-10, ISSN 0360-3016 
www.intechopen.com
 
Modern Practices in Radiation Therapy 
 
38
Foro Arnalot, P., A. V. Fontanals, J. C. Galceran, F. Lynd, X. S. Latiesas, N. R. de Dios, A. R. 
Castillejo, et al. (2008). Randomized clinical trial with two palliative radiotherapy 
regimens in painful bone metastases: 30 gy in 10 fractions compared with 8 gy in 
single fraction. Radiotherapy and Oncology : Journal of the European Society for 
Therapeutic Radiology and Oncology, Vol.89, No.2, pp. 150-5, ISSN 0167-8140 
Gagnon, G. J., N. M. Nasr, J. J. Liao, I. Molzahn, D. Marsh, D. McRae, & Sr Henderson FC. 
(2009). Treatment of spinal tumors using cyberknife fractionated stereotactic 
radiosurgery: Pain and quality-of-life assessment after treatment in 200 patients. 
Neurosurgery, Vol.64, No.2, pp. 306-7, ISSN 1524-4040 
Gaze, M. N., C. G. Kelly, G. R. Kerr, A. Cull, V. J. Cowie, A. Gregor, G. C. Howard, & A. 
Rodger. (1997). Pain relief and quality of life following radiotherapy for bone 
metastases: A randomised trial of two fractionation schedules. Radiotherapy and 
Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 
Vol.45, No.2, pp. 109-16, ISSN 0167-8140 
Gerszten, P. C., S. A. Burton, C. Ozhasoglu, & W. C. Welch. (2007). Radiosurgery for spinal 
metastases: Clinical experience in 500 cases from a single institution. Spine, Vol.32, 
No.2, pp. 193-9, ISSN 1528-1159 
Gibbs, I. C., P. Kamnerdsupaphon, M. R. Ryu, R. Dodd, M. Kiernan, S. D. Chang, & J. R. 
Adler Jr. (2007). Image-guided robotic radiosurgery for spinal metastases. 
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology 
and Oncology, Vol.82, No.2, pp. 185-90, ISSN 0167-8140 
Gomez, D. R., M. A. Hunt, A. Jackson, W. P. O'Meara, E. N. Bukanova, M. J. Zelefsky, Y. 
Yamada, & K. E. Rosenzweig. (2009). Low rate of thoracic toxicity in palliative 
paraspinal single-fraction stereotactic body radiation therapy. Radiotherapy and 
Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 
Vol.93, No.3, pp. 414-8, ISSN 0167-8140 
Gripp, S., S. Mjartan, E. Boelke, & R. Willers. (2010). Palliative radiotherapy tailored to life 
expectancy in end-stage cancer patients: Reality or myth? Cancer, Vol.116, No.13, 
pp. 3251-6, ISSN 1097-0142 
Halperin, Edward C., Carlos A. Perez, Luther W. Brady, & Ralph Erskine Conrad Memorial 
Fund. (Eds.). (2008). Perez and brady's principles and practice of radiation oncology, (5th 
ed.), Wolters Kluwer Health/Lippincott Williams & Wilkins, ISBN 978-0781763691, 
Philadelphia 
Hayat, M. J., N. Howlader, M. E. Reichman, & B. K. Edwards. (2007). Cancer statistics, trends, 
and multiple primary cancer analyses from the surveillance, epidemiology, and end 
results (SEER) program. The Oncologist, Vol.12, No.1, pp. 20-37, ISSN 1083-7159 
Hissoiny, S., B. Ozell, & P. Despres. (2010). A convolution-superposition dose calculation 
engine for GPUs. Medical Physics, Vol.37, No.3, pp. 1029-37, ISSN 0094-2405 (2009). 
Fast convolution-superposition dose calculation on graphics hardware. Medical 
Physics, Vol.36, No.6, pp. 1998-2005, ISSN 0094-2405 
Jemal, A., R. Siegel, J. Xu, & E. Ward. (2010). Cancer statistics, 2010. CA: A Cancer Journal for 
Clinicians, ISSN 1542-4863 
Kapatoes, J. M., G. H. Olivera, J. P. Balog, H. Keller, P. J. Reckwerdt, & T. R. Mackie. (2001). 
On the accuracy and effectiveness of dose reconstruction for tomotherapy. Physics 
in Medicine and Biology, Vol.46, No.4, pp. 943-66, ISSN 1361-6560 
www.intechopen.com
 
STAT RAD: A Potential Real-Time Radiation Therapy Workflow 
 
39 
Kapatoes, J. M., G. H. Olivera, K. J. Ruchala, J. B. Smilowitz, P. J. Reckwerdt, & T. R. Mackie. 
(2001). A feasible method for clinical delivery verification and dose reconstruction 
in tomotherapy. Medical Physics, Vol.28, No.4, pp. 528-42, ISSN 0094-2405 
Langen, K. M., S. L. Meeks, D. O. Poole, T. H. Wagner, T. R. Willoughby, P. A. Kupelian, K. 
J. Ruchala, J. Haimerl, & G. H. Olivera. (2005). The use of megavoltage CT (MVCT) 
images for dose recomputations. Physics in Medicine and Biology, Vol.50, No.18, pp. 
4259-76, ISSN 1361-6560 
Langendijk, J. A., G. P. ten Velde, N. K. Aaronson, J. M. de Jong, M. J. Muller, & E. F. 
Wouters. (2000). Quality of life after palliative radiotherapy in non-small cell lung 
cancer: A prospective study. International Journal of Radiation Oncology, Biology, 
Physics, Vol.47, No.1, pp. 149-55, ISSN 0360-3016 
Lipton, A. (2010). Bone continuum of cancer. American Journal of Clinical Oncology, Vol.33, 
No.3 Suppl, pp. S1-7, ISSN 02773732   
McGuire, D. B. (2004). Occurrence of cancer pain. Journal of the National Cancer 
Institute.Monographs, Vol.32, pp. 51-6, ISSN 1745-6614 
McIntosh, A., N. Dunlap, K. Sheng, C. C. Geezey, C. B. Turner, L. Blackhall, G. Weiss, E. 
Lappinen, J. M. Larner, & P. W. Read. (2010). Helical tomotherapy-based STAT RT: 
Dosimetric evaluation for clinical implementation of a rapid radiation palliation 
program. Medical Dosimetry, Vol.35, No.4, pp. 280-6, ISSN 0958-3947 
McNutt, T. R., T. R. Mackie, & B. R. Paliwal. (1997). Analysis and convergence of the 
iterative convolution/superposition dose reconstruction technique for multiple 
treatment beams and tomotherapy. Medical Physics, Vol.24, No.9, pp. 1465-76, ISSN 
0094-2405 
McNutt, T. R., T. R. Mackie, P. Reckwerdt, N. Papanikolaou, & B. R. Paliwal. (1996). 
Calculation of portal dose using the convolution/superposition method. Medical 
Physics, Vol.23, No.4, pp. 527-35, ISSN 0094-2405 
Mijnheer, B. (2008). State of the art of in vivo dosimetry. Radiation Protection Dosimetry, 
Vol.131, No.1, pp. 117-22, ISSN 1742-3406 
Nelson, J. W., D. S. Yoo, J. H. Sampson, R. E. Isaacs, N. A. Larrier, L. B. Marks, F. F. Yin, Q. J. 
Wu, Z. Wang, & J. P. Kirkpatrick. (2009). Stereotactic body radiotherapy for lesions 
of the spine and paraspinal regions. International Journal of Radiation Oncology, 
Biology, Physics Vol.73, No.5, pp. 1369-75, ISSN 0360-3016 
Onishi, H., H. Shirato, Y. Nagata, M. Hiraoka, M. Fujino, K. Gomi, K. Karasawa, et al. (2010). 
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung 
cancer: Can SBRT be comparable to surgery? International Journal of Radiation 
Oncology, Biology, Physics, (In press), ISSN 0360-3016 
Read, P. W. (2007). Sterotactic body radiation therapy: 2007 update. Community Oncology, 
Vol.4, No.10, pp. 616-20, ISSN 1548-5315 
Rose, P. S., I. Laufer, P. J. Boland, A. Hanover, M. H. Bilsky, J. Yamada, & E. Lis. (2009). Risk 
of fracture after single fraction image-guided intensity-modulated radiation 
therapy to spinal metastases. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, Vol.27, No.30, pp. 5075-9, ISSN 1527-7755 
Rusthoven, K. E., B. D. Kavanagh, H. Cardenes, V. W. Stieber, S. H. Burri, S. J. Feigenberg, 
M. A. Chidel, et al. (2009). Multi-institutional phase I/II trial of stereotactic body 
radiation therapy for liver metastases. Journal of Clinical Oncology : Official Journal of 
the American Society of Clinical Oncology, Vol.27, No.10, pp. 1572-8, ISSN 1527-7755 
www.intechopen.com
 
Modern Practices in Radiation Therapy 
 
40
Ryu, S., R. Jin, J. Y. Jin, Q. Chen, J. Rock, J. Anderson, & B. Movsas. (2008). Pain control by 
image-guided radiosurgery for solitary spinal metastasis. Journal of Pain and 
Symptom Management, Vol.35, No.3, pp. 292-8, ISSN 0885-3924 
Sahgal, A., L. Ma, I. Gibbs, P. C. Gerszten, S. Ryu, S. Soltys, V. Weinberg, et al. (2010). Spinal 
cord tolerance for stereotactic body radiotherapy. International Journal of Radiation 
Oncology, Biology, Physics, Vol.77, No.2, pp. 548-53, ISSN 0360-3016 
Scarantino, C. W., D. M. Ruslander, C. J. Rini, G. G. Mann, H. T. Nagle, & R. D. Black. (2004). 
An implantable radiation dosimeter for use in external beam radiation therapy. 
Medical Physics, Vol.31, No.9, pp. 2658-71, ISSN 0094-2405 
Schulman, K. L., & J. Kohles. (2007). Economic burden of metastatic bone disease in the U.S. 
Cancer, Vol.109, No.11, pp. 2334-42, ISSN 1097-0142 
Sheng, K., R. Jones, W. Yang, B. Schneider, Q. Chen, G. Sobering, G. H. Olivera, & P. W. 
Read. (2011). 3D dose verification using tomotherapy CT detector array. 
International Journal of Radiation Oncology, Biology, Physics, (In press), ISSN 0360-3016 
Siewerdsen, J. H., & D. A. Jaffray. (2001). Cone-beam computed tomography with a flat-
panel imager: Magnitude and effects of x-ray scatter. Medical Physics, Vol.28, No.2, 
pp. 220-31, ISSN 0094-2405 
Timmerman, R., R. Paulus, J. Galvin, J. Michalski, W. Straube, J. Bradley, A. Fakiris, et al. 
(2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. 
JAMA : The Journal of the American Medical Association, Vol.303, No.11, pp. 1070-6, 
ISSN 0098-7484 
Ulin, K., M. M. Urie, & J. M. Cherlow. (2010). Results of a multi-institutional benchmark test 
for cranial CT/MR image registration. International Journal of Radiation Oncology, 
Biology, Physics, Vol.77, No.5, pp. 1584-9, ISSN 0360-3016 
Wagner, T. H., S. L. Meeks, F. J. Bova, W. A. Friedman, T. R. Willoughby, P. A. Kupelian, & 
W. Tome. (2007). Optical tracking technology in stereotactic radiation therapy. 
Medical Dosimetry, Vol.32, No.2, pp. 111-20, ISSN 0958-3947 
Wiersma, R. D., Z. Wen, M. Sadinski, K. Farrey, & K. M. Yenice. (2010). Development of a 
frameless stereotactic radiosurgery system based on real-time 6D position 
monitoring and adaptive head motion compensation. Physics in Medicine and 
Biology, Vol.55, No.2, pp. 389-401, ISSN 1361-6560 
Wu, J. S., R. Wong, M. Johnston, A. Bezjak, T. Whelan, & Cancer Care Ontario Practice 
Guidelines Initiative Supportive Care Group. (2003). Meta-analysis of dose-
fractionation radiotherapy trials for the palliation of painful bone metastases. 
International Journal of Radiation Oncology, Biology, Physics Vol.55, No.3, pp. 594-605, 
ISSN 0360-3016 
www.intechopen.com
Modern Practices in Radiation Therapy
Edited by Dr. Gopishankar Natanasabapathi
ISBN 978-953-51-0427-8
Hard cover, 370 pages
Publisher InTech
Published online 30, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer is the leading cause of death in economically developed countries and the second leading cause of
death in developing countries. It is an enormous global health encumbrance, growing at an alarming pace.
Global statistics show that in 2030 alone, about 21.4 million new cancer cases and 13.2 million cancer deaths
are expected to occur, simply due to the growth, aging of the population, adoption of new lifestyles and
behaviors. Amongst the several modes of treatment for cancer available, Radiation treatment has a major
impact due to technological advancement in recent times. This book discusses the pros and cons of this
treatment modality. This book "Modern Practices in Radiation Therapy" has collaged topics contributed by top
notch professionals and researchers all around the world.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
David Wilson, Ke Sheng, Wensha Yang, Ryan Jones, Neal Dunlap and Paul Read (2012). STAT RAD: A
Potential Real-Time Radiation Therapy Workflow, Modern Practices in Radiation Therapy, Dr. Gopishankar
Natanasabapathi (Ed.), ISBN: 978-953-51-0427-8, InTech, Available from:
http://www.intechopen.com/books/modern-practices-in-radiation-therapy/stat-rad-a-potential-real-time-
radiation-therapy-workflow
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
